Clodagh Kearney

Ms. Clodagh Kearney


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Biomaterials
Verified
Journal Article
Closed access
Tanya J. LevingstoneTanya J. Levingstone
Tanya J. Levingstone
ARAshwanth Ramesh
Ashwanth Ramesh
RBRobert Thomas Brady
Robert Thomas Brady
PBPieter A.J. Brama
Pieter A.J. Brama
CKClodagh Kearney
Clodagh Kearney
Fergal O'BrienFergal O'Brien
Fergal O'Brien

29 April 2010 in Veterinary Surgery
Verified
Journal Article
Closed access
PDF file
TRTom M. Russell
Tom M. Russell
CKClodagh Kearney
Clodagh Kearney
PPPatrick J. Pollock
Patrick J. Pollock

26 June 2018 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
SSSvenja Sladek
Svenja Sladek
CKClodagh Kearney
Clodagh Kearney
DCDaniel Crean
Daniel Crean
PBPieter A. J. Brama
Pieter A. J. Brama
LTLidia Tajber
Lidia Tajber
David BraydenDavid Brayden
David Brayden
Polyelectrolyte nanoparticle constructs (NPs) comprising salmon calcitonin (sCT), chitosan (CS), and hyaluronic acid (HA) were previously established as having anti-inflammatory potential when injected via the intra-articular (i.a.) route to a mouse model. We attempted to translate the formulation to a large animal model, the lipopolysaccharide (LPS)-stimulated equine model of joint inflammation. The aim was to manufacture under aseptic conditions to produce sterile pyrogen-free NPs, to confirm physicochemical characteristics, and to test toxicity and efficacy in a pilot study. NP dispersions were successfully formulated using pharmaceutical-grade source materials and were aseptically manufactured under GMP-simulated conditions in a grade A modular aseptic processing workstation. The NP formulation had no detectable pathogen or endotoxin contamination. NPs were then tested versus a lactated Ringer’s solution control following single i.a. injections to the radiocarpal joints of two groups of four horses pre-treated with LPS, followed by arthrocentesis at set intervals over 1 week. There was no evidence of treatment-related toxicity over the period. While there were no differences between clinical read-outs of the NP and the control, two synovial fluid-derived biomarkers associated with cartilage turnover revealed a beneficial effect of NPs. In conclusion, NPs comprising well-known materials were manufactured for an equine i.a.-injectable pilot study and yielded no NP-attributable toxicity. Evidence of NP-associated benefit at the level of secondary endpoints was detected as a result of decreases in synovial fluid inflammatory biomarkers.

22 June 2022 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
CKClodagh Kearney
Clodagh Kearney
SKSohrab Khatab
Sohrab Khatab
GBGerben M. van Buul
Gerben M. van Buul
SPSaskia G. M. Plomp
Saskia G. M. Plomp
NKNicoline M. Korthagen
Nicoline M. Korthagen
PBPieter A. J. Brama
Pieter A. J. Brama
Background: Allogenic mesenchymal stem cell (MSC) secretome is a novel intra-articular therapeutic that has shown promise inin vitroand small animal models and warrants further investigation.Objectives: To investigate if intra-articular allogenic MSC-secretome has anti-inflammatory effects using an equine model of joint inflammation.Study Design: Randomized positively and negatively controlled experimental study.Method: In phase 1, joint inflammation was induced bilaterally in radiocarpal joints of eight horses by injecting 0.25 ng lipopolysaccharide (LPS). After 2 h, the secretome of INFy and TNFα stimulated allogeneic equine MSCs was injected in one randomly assigned joint, while the contralateral joint was injected with medium (negative control). Clinical parameters (composite welfare scores, joint effusion, joint circumference) were recorded, and synovial fluid samples were analyzed for biomarkers (total protein, WBCC; eicosanoid mediators, CCL2; TNFα; MMP; GAGs; C2C; CPII) at fixed post-injection hours (PIH 0, 8, 24, 72, and 168 h). The effects of time and treatment on clinical and synovial fluid parameters and the presence of time-treatment interactions were evaluated. For phase 2, allogeneic MSC-secretome vs. allogeneic equine MSCs (positive control) was tested using a similar methodology.Results: In phase 1, the joint circumference was significantly (p< 0.05) lower in the MSC-secretome treated group compared to the medium control group at PIH 24, and significantly higher peak synovial GAG values were noted at PIH 24 (p< 0.001). In phase 2, no significant differences were noted between the treatment effects of MSC-secretome and MSCs.Main Limitations: This study is a controlled experimental study and therefore cannot fully reflect natural joint disease. In phase 2, two therapeutics are directly compared and there is no negative control.Conclusions: In this model of joint inflammation, intra-articular MSC-secretome injection had some clinical anti-inflammatory effects. An effect on cartilage metabolism, evident as a rise in GAG levels was also noted, although it is unclear whether this could be considered a beneficial or detrimental effect. When directly comparing MSC-secretome to MSCs in this model results were comparable, indicating that MSC-secretome could be a viable off-the-shelf alternative to MSC treatment.

20 November 2013 in Equine Veterinary Journal
Verified
Journal Article
Closed access
PDF file
CKClodagh Kearney
Clodagh Kearney
Conor BuckleyConor Buckley
Conor Buckley
FJFlorien Jenner
Florien Jenner
PMP. Moissonnier
P. Moissonnier
PBP. A. J. Brama
P. A. J. Brama

6 December 2020 in Equine Veterinary Journal
Verified
Journal Article
Closed access
PDF file
CKClodagh Kearney
Clodagh Kearney
NKNicoline M. Korthagen
Nicoline M. Korthagen
SPSaskia G. M. Plomp
Saskia G. M. Plomp
MLMargot C. Labberté
Margot C. Labberté
JGJanny de Grauw
Janny de Grauw
PBPieter A. J. Brama
Pieter A. J. Brama